Who is sponsoring NCT07526090?

NCT07526090 is sponsored by Qianfoshan Hospital.

What drugs are being tested in NCT07526090?

Interventions in NCT07526090: Retrospective Data Collection.

What condition does NCT07526090 study?

NCT07526090 studies Colorectal Cancer.

Is NCT07526090 still recruiting?

NCT07526090 is currently completed. Last updated 13 April 2026.

Last reviewed 2026-04-13 · How we verify

NCT07526090

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Identification of Regional Epidemiological Characteristics and Key Prognostic Factors of Colorectal Cancer in Xinjiang and Shandong

Completed Last updated 13 April 2026

What this trial tests

trial testing Retrospective Data Collection in Colorectal Cancer in 500 participants. Completed in 31 December 2020.

Timeline

1 January 2016

Primary endpoint
31 December 2020

31 December 2020

Quick facts

Lead sponsor	Qianfoshan Hospital
Status	Completed
Study type	OBSERVATIONAL
Enrollment	500
Start date	1 January 2016
Primary completion	31 December 2020
Estimated completion	31 December 2020
Sites	1 location across China

Drugs / interventions tested

Retrospective Data Collection

Conditions studied

Colorectal Cancer — all drugs for Colorectal Cancer →

Sponsor

Qianfoshan Hospital

Who can join

Adults 18 to 120, any sex, with Colorectal Cancer. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This is a multicenter, retrospective, cross-sectional observational study aiming to investigate the 5-year overall survival (OS) rate of colorectal cancer (CRC) patients in Xinjiang and Shandong provinces of China. A total of no less than 500 pathologically confirmed CRC patients from 7 medical centers during January 1, 2016 to December 31, 2020 will be enrolled. We will collect and analyze the demographic characteristics, lifestyle, clinical pathological features, treatment patterns and survival prognosis data of patients, explore the regional differences of CRC and its key prognostic factors, and construct a CRC prognostic prediction model. The results will provide theoretical guidance for clinical practice and the formulation of public health policies.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other recruiting trials for Colorectal Cancer

Currently open trials in the same condition.

NCT07152821 — Botensilimab + Balstilimab vs Best Supportive Care as Therapy in Chemo-refractory, Unresectable, Colorectal Adenocarcino · Phase 3 · recruiting
NCT07353645 — KRAS Neoantigen Nanovaccine as Adjuvant Therapy for Colorectal Cancer/Pancreatic Cancer · Phase 1, PHASE2 · recruiting
NCT07432633 — [18F]FPyQCP PET Imaging of Fibroblast Activation Protein in Selected Oncology Indications · Phase 1, PHASE2 · recruiting
NCT07523919 — Functional and Respiratory Determinants of Long-Term Colorectal Cancer Outcomes · recruiting
NCT07529301 — Functional and Respiratory Predictors of Early Postoperative Outcomes · recruiting

Other Qianfoshan Hospital trials

Trials by the same sponsor.

NCT05727618 — The Effect of Pituitrin on the Patients With Pulmonary Hypertension Undergoing Cardiac Surgery · NA · suspended
NCT06837831 — Mepilex Lite Dressings for the Treatment of Acute Radiation Dermatitis of Anal Canal Skin · NA · recruiting
NCT07260760 — Clinical Comprehensive Evaluation of Neuroprotective Drugs for Acute Ischemic Stroke · not yet recruiting
NCT07362667 — A Study of the Efficacy and Safety of Bronchoscopic Airway Clearance and Amphotericin B Spraying in Patients With ABPA · recruiting
NCT07271849 — Nalbuphine Timing Effects on Hemodynamics and Analgesia in Elderly Patients · Phase 4 · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT07526090 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Qianfoshan Hospital
Last refreshed: 13 April 2026

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT07526090.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing